TScan Therapeutics, Inc.
TCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001783328
No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in TScan Therapeutics, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 27
- +27 vs. Q2 2021
- Shares held
- 10.1M
- +10.1M vs. Q2 2021
- Total value
- $83.5M
- +$83.5M vs. Q2 2021
- New holders
- 27
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TCRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 60 | $35.1M |
| Q1 2026 | 60 | $32.8M |
| Q4 2025 | 61 | $30.7M |
| Q3 2025 | 73 | $62.9M |
| Q2 2025 | 81 | $51.8M |
| Q1 2025 | 92 | $55.4M |
| Q4 2024 | 89 | $126.2M |
| Q3 2024 | 89 | $208.3M |
| Q2 2024 | 81 | $242.6M |
| Q1 2024 | 66 | $272.3M |
| Q4 2023 | 54 | $186.1M |
| Q3 2023 | 32 | $73.2M |
| Q2 2023 | 28 | $69.9M |
| Q1 2023 | 28 | $20.3M |
| Q4 2022 | 28 | $14.8M |
| Q3 2022 | 26 | $29.0M |
| Q2 2022 | 24 | $30.4M |
| Q1 2022 | 25 | $26.3M |
| Q4 2021 | 29 | $44.4M |
| Q3 2021 | 27 | $83.5M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding TScan Therapeutics, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock Inc. | 1,500,577 | $12.5M | 0.00% | +1,500,577 | New |
| Baker Bros. Advisors LP | 1,425,000 | $11.9M | 0.05% | +1,425,000 | New |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 1,282,976 | $10.7M | 0.14% | +1,282,976 | New |
| Ra Capital Management, L.P. | 1,255,317 | $10.5M | 0.15% | +1,255,317 | New |
| Deer IX & Co. Ltd. | 1,245,505 | $9.35M | 0.96% | +1,245,505 | New |
| Alphabet Inc. | 1,077,080 | $8.98M | 0.21% | +1,077,080 | New |
| DC Funds, LP | 630,000 | $5.25M | 20.63% | +630,000 | New |
| Adage Capital Partners GP, L.L.C. | 496,583 | $4.14M | 0.01% | +496,583 | New |
| Vanguard Group Inc | 444,894 | $3.71M | 0.00% | +444,894 | New |
| Tekla Capital Management LLC | 200,000 | $1.67M | 0.05% | +200,000 | New |
| Wellington Management Group LLP | 139,566 | $1.16M | 0.00% | +139,566 | New |
| Monashee Investment Management LLC | 100,000 | $834.0K | 0.15% | +100,000 | New |
| Caas Capital Management LP | 75,000 | $626.0K | 0.05% | +75,000 | New |
| Norges Bank | 60,000 | $500.0K | 0.00% | +60,000 | New |
| DC Investments Management, LLC | 35,563 | $297.0K | 0.55% | +35,563 | New |
| Millennium Management LLC | 30,240 | $252.0K | 0.00% | +30,240 | New |
| Morgan Stanley | 28,236 | $235.0K | 0.00% | +28,236 | New |
| Two Sigma Investments, LP | 22,817 | $190.0K | 0.00% | +22,817 | New |
| Schonfeld Strategic Advisors LLC | 22,200 | $185.0K | 0.00% | +22,200 | New |
| Two Sigma Advisers, LP | 13,000 | $108.0K | 0.00% | +13,000 | New |
| Geode Capital Management, LLC | 12,786 | $106.0K | 0.00% | +12,786 | New |
| State Street Corp | 12,200 | $102.0K | 0.00% | +12,200 | New |
| Citadel Advisors LLC | 11,922 | $99.0K | 0.00% | +11,922 | New |
| Goldman Sachs Group Inc | 11,531 | $96.0K | 0.00% | +11,531 | New |
| Royal Bank of Canada | 1,000 | $8.00K | 0.00% | +1,000 | New |
| UBS Group AG | 946 | $8.00K | 0.00% | +946 | New |
| Wells Fargo & Company | 41 | $0 | 0.00% | +41 | New |